Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Our AI ranks Vaso Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Vaso Corp is a small-cap company with a market capitalization of $51M. It ranks number 19 by market capitalization among the 30 Electromedical & Electrotherapeutic Apparatus issuers in our coverage with a current forecast.
For VASO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 2.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 5.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, VASO included.
Follow VASO free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
| Metric | VASO | Rank |
|---|---|---|
| Market Cap | $51M | 19/30 |
| P/B Ratio | 1.75x | 17/23 |
| EPS | $0.00 | – |
| Book Value/Share | $0.17 | – |
| Revenue/Share | $0.46 | – |
| Metric | VASO | Rank |
|---|---|---|
| ROE | 8.6% | 7/19 |
| ROA | 2.9% | 8/24 |
| ROIC | -3.0% | 13/23 |
| Gross Margin | 64.8% | 12/27 |
| Operating Margin | -2.0% | 11/28 |
| Net Margin | 3.1% | 10/22 |
| EBT Margin | 0.1% | 10/28 |
| Tax Rate | -7252.6% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
| Metric | VASO | Rank |
|---|---|---|
| Current Ratio | 1.68x | 19/30 |
| Quick Ratio | 1.65x | 15/29 |
| D/E Ratio | 1.94x | 4/25 |
| Financial Leverage | 2.94x | 4/25 |
| Interest Coverage | -116.2x | 24/30 |
| Working Capital | $22M | 14/29 |
| Metric | VASO | Rank |
|---|---|---|
| Operating Cash Flow | $8M | 10/30 |
| OCF Growth YoY | 0.9% | 6/9 |
| Metric | VASO | Rank |
|---|---|---|
| Asset Turnover | 0.93x | 5/19 |
| Receivables Turnover | 24.0x | 3/20 |
| Inventory Turnover | 33.7x | 2/27 |
| Fixed Assets Turnover | 794.3x | 1/20 |
| Days Sales Outstanding | 15 days | 18/20 |
| Days Inventory | 11 days | 26/27 |
| Payables Period | 9 days | 24/24 |
| Cash Conversion Cycle | 17 days | 15/19 |
| Metric | VASO | Rank |
|---|---|---|
| Total Revenue | $80M | 9/19 |
| Operating Income | -$2M | 13/30 |
| Net Income | $2M | 9/24 |
| R&D Expense | $780K | 23/28 |
| SG&A Expense | $48M | 11/26 |
| Cost of Goods Sold | $28M | 12/27 |
| Metric | VASO | Rank |
|---|---|---|
| Shares Outstanding | 176M | – |
| EPS Growth | -100.0% | 6/7 |
| Total Current Assets | $55M | 64.2% of assets |
| Cash & Short-term Investments | $38M | 44.6% of assets |
| Accounts Receivable | $3M | 3.9% of assets |
| Inventory | $840K | 1.0% of assets |
| Total Liabilities | $57M | 66.0% of assets |
| Short-term Debt | $32M | 37.5% of assets |
Companies classified under the same SEC industry code as Vaso Corp (Electromedical & Electrotherapeutic Apparatus): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| VASO Vaso Corp | ▲ | $51M |
| MDT Medtronic Plc | ▼ | $121.20B |
| ITGR Integer Holdings Corp | ▼ | $4.31B |
| LIVN Livanova Plc | ▼ | $4.27B |
| TMDX Transmedics Group, Inc. | ▲ | $2.45B |
| BLFS Biolife Solutions Inc | ▶ | $1.89B |
| AXGN Axogen, Inc. | ▲ | $1.86B |
| CNMD Conmed Corp | ▼ | $1.40B |
| CBLL Ceribell, Inc. | ▲ | $961M |
| INMD Inmode Ltd. | ▼ | $814M |
| CV Capsovision, Inc | ▶ | $327M |
| ELMD Electromed, Inc. | ▼ | $229M |
| FOCL Edap Tms Sa | ▲ | $153M |
| STXS Stereotaxis, Inc. | ▶ | $101M |
| VANI Vivani Medical, Inc. | ▶ | $101M |
| NRXS Neuraxis, Inc | ▲ | $97M |
| HYPR Hyperfine, Inc. | ▲ | $75M |
| OM Outset Medical, Inc. | ▲ | $74M |
| ECOR Electrocore, Inc. | ▲ | $71M |
| POSC Positron Corp | ▲ | $51M |
| QTI Qt Imaging Holdings, Inc. | ▶ | $35M |
| POCI Precision Optics Corporation, Inc. | ▲ | $34M |
| ITOC Itonic Holdings Ltd | ▼ | $28M |
| GTHP Guided Therapeutics Inc | ▲ | $18M |
| IRIX Iridex Corp | ▲ | $14M |
| NDRA Endra Life Sciences Inc. | ▶ | $7M |
| ADMT Adm Tronics Unlimited, Inc. | ▶ | $3M |
| NUWE Nuwellis, Inc. | ▼ | $2M |
| NXL Nexalin Technology, Inc. | ▼ | $2M |
| ESMC Escalon Medical Corp | ▲ | $1M |
| HCIL Hongchang International Co., Ltd | ▼ | N/A |
| YBGJ Yubo International Biotech Ltd | ▶ | N/A |
PLAINVIEW, N.Y., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso" or the "Company") (OTCQX: VASO) announced that on August 5, 2024, the U.S. Securities and Exchange Commission ("SEC") ...
Merger with Achari Ventures Holdings Corp. I (NASDAQ:AVHI) expected to improve capital market access for existing and prospective investors of Vaso Corporation (OTCQX:VASO). The transaction values ...
PLAINVIEW, N.Y., May 15, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional ...
Our AI ranks Vaso Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For VASO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 2.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 5.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Vaso Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
32 issuers in our coverage, VASO included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Integer Holdings Corp (ITGR), Livanova Plc (LIVN), Transmedics Group, Inc. (TMDX), Biolife Solutions Inc (BLFS), Axogen, Inc. (AXGN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.